[Kaletra (lopinavir/ritonavir--a new HIV protease inhibitor].
Ershov
F I
FI
N. F. Gamaleya Research Institute of Epidemiology and Microbiology, Research Centre of Drug Evaluation, Moscow.
Kas'ianova
N V
NV
Vasil'ev
A N
AN
D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D061466:Lopinavir; D011744:Pyrimidinones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019438:Ritonavir / Q000009:adverse effects / Q000627:therapeutic use*
D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir
Kaletra (lopinavir/ritonavir)--novyĭ ingibitor VICh-proteaz]